Following males with haemophilia A on long-term Esperoct prophylaxis
Collects side effects and how well Esperoct works in males with haemophilia A.
Plain-language title generated from the registry record
Registry title: A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
Key facts
- Where
- Málaga, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for males with moderate or severe haemophilia A who are starting treatment with Esperoct®. The study follows how well it works and any side effects over several years.
- Age
- Males of all ages, according to the local label.
- Sex
- Male only.
- Disease stage
- Severe or moderate haemophilia A.
- Earlier treatment
- The patient and doctor have decided to start Esperoct® on their own, before and apart from the decision to join this study.
Main reasons for not taking part
- Took part in this study before
- Known or suspected allergy to N8-GP or related products
- Mental incapacity, unwillingness or language barriers that prevent understanding and cooperation
- Suspected or present FVIII inhibitors when joining
Read by machine on 9 November 2026.
Where in Spain
- Hospital Regional Universitario de MalagaMálaga, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT04574076
- Record updated
- 22 December 2025
- Original description
This study will collect information on side effects and how well Esperoct® (turoctocog alfa pegol (N8-GP)) works during long-term treatment (prophylaxis) in males with haemophilia A. Participants in this study will get the same treatment as they would normally get, if they were not participating in the study. All visits at the clinic are done in the same way as participants are used to, when visiting their doctor. During visits at the clinic participants might be asked for some relevant tests if considered useful by the study doctor. During the visits the study doctor might ask if participants had any side effects since the last study visit. Participants will be asked to note down in their own diary the number of bleeds and how these were treated, as well as their regular prophylaxis. Participation in the study will last for about 5-7 years, depending on when participants join the study. Participants are free to leave the study at any time and for any reason. This will not affect their current and future medical care.Read full original descriptionShow less
A Multinational, Prospective, Open Labelled, Non-controlled, Non-interventional Post-authorisation Study of Turoctocog Alfa Pegol (N8-GP) During Long-term Routine Prophylaxis and Treatment of Bleeding Episodes in Patients With Haemophilia A
This study will collect information on side effects and how well Esperoct® (turoctocog alfa pegol (N8-GP)) works during long-term treatment (prophylaxis) in males with haemophilia A. Participants in this study will get the same treatment as they would normally get, if they were not participating in the study. All visits at the clinic are done in the same way as participants are used to, when visiting their doctor. During visits at the clinic participants might be asked for some relevant tests if considered useful by the study doctor. During the visits the study doctor might ask if participants had any side effects since the last study visit. Participants will be asked to note down in their own diary the number of bleeds and how these were treated, as well as their regular prophylaxis. Participation in the study will last for about 5-7 years, depending on when participants join the study. Participants are free to leave the study at any time and for any reason. This will not affect their current and future medical care.
Inclusion: Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol); The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study; Male patients of all ages, according to local label, are allowed in this study; Diagnosis of severe or moderate Haemophilia A.
Exclusion: Previous participation in this study. Participation is defined as having given informed consent in this study; Clinical suspicion or presence of FVIII inhibitors at time of inclusion; Known or suspected hypersensitivity to N8-GP or related products; Mental incapacity, unwillingness or language barriers precluding adequate understanding and cooperation.